 |
|
|
| |
Sustained Virologic Response Rates and Viral Resistance Profiles Were Similar in Patients Treated with a Telaprevir-based Regimen Regardless of Liver Fibrosis Stage
|
| |
| |
Reported by Jules Levin
AASLD Nov 5-8 2011 SF
P Marcellin1, JC Sullivan2, MW Fried3, TL Kieffer2, GM Dusheiko4, EC Martin2, DR Nelson5, AM Di Bisceglie6, CI Wright2, S George2, L Bengtsson2, DJ Bartels2, GT Everson7, N Adda2
1 University of Paris Clichy, Clichy, France; 2 Vertex Pharmaceuticals Incorporated, Cambridge, MA, United States; 3 University of North Carolina at Chapel Hill, Chapel Hill, NC, United States; 4 Royal Free and University College, London, United Kingdom; 5 University of Florida, Gainesville, FL, United States; 6 Saint Louis University School of Medicine, Saint Louis, MO, United States; 7 University of Colorado Denver, Aurora, CO, United States.
References
1. INCIVEK [package insert]. Cambridge, MA: Vertex Pharmaceuticals Incorporated; 2011.
2. INCIVO [EU summary of product characteristics]. Beerse, Belgium: Tibotec; 2011.
3. INCIVEK [Canada product monograph]. Cambridge, MA: Vertex Pharmaceuticals Incorporated; 2011.
4. Jacobson IM et al. N Engl J Med 2011;364:2405-16.
5. Sherman KE et al. N Engl J Med 2011;365:1014-24. [Erratum: N Engl J Med. 2011;365:1551].
|
| |
|
|
|
|
|
